level1 / llama3

META LLAMA 3 COMMUNITY LICENSE AGREEMENT Meta Llama 3 Version Release Date: April 18, 2024 “Agreement” means the terms and conditions for use, reproduction, distribution and modification of the Llama Materials set forth herein. “Documentation” means the specifications, manuals and documentation accompanying Meta Llama 3 distributed by Meta at https://llama.meta.com/get-started/. “Licensee” or “you” means you, or your employer or any other person or entity (if you are entering into this Agreement on such person or entity’s behalf), of the age required under applicable laws, rules or regulations to provide legal consent and that has legal authority to bind your employer or such other person or entity if you are entering in this Agreement on their behalf. “Meta Llama 3” means the foundational large language models and software and algorithms, including machine-learning model code, trained model weights, inference-enabling code, training-enabling code, fine-tuning enabling code and other elements of the foregoing distributed by Meta at https://llama.meta.com/llama-downloads. “Llama Materials” means, collectively, Meta’s proprietary Meta Llama 3 and Documentation (and any portion thereof) made available under this Agreement. “Meta” or “we” means Meta Platforms Ireland Limited (if you are located in or, if you are an entity, your principal place of business is in the EEA or Switzerland) and Meta Platforms, Inc. (if you are located outside of the EEA or Switzerland). By clicking “I Accept” below or by using or distributing any portion or element of the Llama Materials, you agree to be bound by this Agreement. 1. License Rights and Redistribution. a. Grant of Rights. You are granted a non-exclusive, worldwide, non-transferable and royalty-free limited license under Meta’s intellectual property or other rights owned by Meta embodied in the Llama Materials to use, reproduce, distribute, copy, create derivative works of, and make modifications to the Llama Materials. b. Redistribution and Use. i. If you distribute or make available the Llama Materials (or any derivative works thereof), or a product or service that uses any of them, including another AI model, you shall (A) provide a copy of this Agreement with any such Llama Materials; and (B) prominently display “Built with Meta Llama 3” on a related website, user interface, blogpost, about page, or product documentation. If you use the Llama Materials to create, train, fine tune, or otherwise improve an AI model, which is distributed or made available, you shall also include “Llama 3” at the beginning of any such AI model name. ii. If you receive Llama Materials, or any derivative works thereof, from a Licensee as part of an integrated end user product, then Section 2 of this Agreement will not apply to you. iii. You must retain in all copies of the Llama Materials that you distribute the following attribution notice within a “Notice” text file distributed as a part of such copies: “Meta Llama 3 is licensed under the Meta Llama 3 Community License, Copyright © Meta Platforms, Inc. All Rights Reserved.” iv. Your use of the Llama Materials must comply with applicable laws and regulations (including trade compliance laws and regulations) and adhere to the Acceptable Use Policy for the Llama Materials (available at https://llama.meta.com/llama3/use-policy), which is hereby incorporated by reference into this Agreement. v. You will not use the Llama Materials or any output or results of the Llama Materials to improve any other large language model (excluding Meta Llama 3 or derivative works thereof). 2. Additional Commercial Terms. If, on the Meta Llama 3 version release date, the monthly active users of the products or services made available by or for Licensee, or Licensee’s affiliates, is greater than 700 million monthly active users in the preceding calendar month, you must request a license from Meta, which Meta may grant to you in its sole discretion, and you are not authorized to exercise any of the rights under this Agreement unless or until Meta otherwise expressly grants you such rights. 3. Disclaimer of Warranty. UNLESS REQUIRED BY APPLICABLE LAW, THE LLAMA MATERIALS AND ANY OUTPUT AND RESULTS THEREFROM ARE PROVIDED ON AN “AS IS” BASIS, WITHOUT WARRANTIES OF ANY KIND, AND META DISCLAIMS ALL WARRANTIES OF ANY KIND, BOTH EXPRESS AND IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. YOU ARE SOLELY RESPONSIBLE FOR DETERMINING THE APPROPRIATENESS OF USING OR REDISTRIBUTING THE LLAMA MATERIALS AND ASSUME ANY RISKS ASSOCIATED WITH YOUR USE OF THE LLAMA MATERIALS AND ANY OUTPUT AND RESULTS. 4. Limitation of Liability. IN NO EVENT WILL META OR ITS AFFILIATES BE LIABLE UNDER ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, PRODUCTS LIABILITY, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, FOR ANY LOST PROFITS OR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY OR PUNITIVE DAMAGES, EVEN IF META OR ITS AFFILIATES HAVE BEEN ADVISED OF THE POSSIBILITY OF ANY OF THE FOREGOING. 5. Intellectual Property. a. No trademark licenses are granted under this Agreement, and in connection with the Llama Materials, neither Meta nor Licensee may use any name or mark owned by or associated with the other or any of its affiliates, except as required for reasonable and customary use in describing and redistributing the Llama Materials or as set forth in this Section 5(a). Meta hereby grants you a license to use “Llama 3” (the “Mark”) solely as required to comply with the last sentence of Section 1.b.i. You will comply with Meta’s brand guidelines (currently accessible at https://about.meta.com/brand/resources/meta/company-brand/ ). All goodwill arising out of your use of the Mark will inure to the benefit of Meta. b. Subject to Meta’s ownership of Llama Materials and derivatives made by or for Meta, with respect to any derivative works and modifications of the Llama Materials that are made by you, as between you and Meta, you are and will be the owner of such derivative works and modifications. c. If you institute litigation or other proceedings against Meta or any entity (including a cross-claim or counterclaim in a lawsuit) alleging that the Llama Materials or Meta Llama 3 outputs or results, or any portion of any of the foregoing, constitutes infringement of intellectual property or other rights owned or licensable by you, then any licenses granted to you under this Agreement shall terminate as of the date such litigation or claim is filed or instituted. You will indemnify and hold harmless Meta from and against any claim by any third party arising out of or related to your use or distribution of the Llama Materials. 6. Term and Termination. The term of this Agreement will commence upon your acceptance of this Agreement or access to the Llama Materials and will continue in full force and effect until terminated in accordance with the terms and conditions herein. Meta may terminate this Agreement if you are in breach of any term or condition of this Agreement. Upon termination of this Agreement, you shall delete and cease use of the Llama Materials. Sections 3, 4 and 7 shall survive the termination of this Agreement. 7. Governing Law and Jurisdiction. This Agreement will be governed and construed under the laws of the State of California without regard to choice of law principles, and the UN Convention on Contracts for the International Sale of Goods does not apply to this Agreement. The courts of California shall have exclusive jurisdiction of any dispute arising out of this Agreement. Meta Llama 3 Acceptable Use Policy Meta is committed to promoting safe and fair use of its tools and features, including Meta Llama 3. If you access or use Meta Llama 3, you agree to this Acceptable Use Policy (“Policy”). The most recent copy of this policy can be found at https://llama.meta.com/llama3/use-policy Prohibited Uses We want everyone to use Meta Llama 3 safely and responsibly. You agree you will not use, or allow others to use, Meta Llama 3 to: 1. Violate the law or others’ rights, including to: a. Engage in, promote, generate, contribute to, encourage, plan, incite, or further illegal or unlawful activity or content, such as: i. Violence or terrorism ii. Exploitation or harm to children, including the solicitation, creation, acquisition, or dissemination of child exploitative content or failure to report Child Sexual Abuse Material iii. Human trafficking, exploitation, and sexual violence iv. The illegal distribution of information or materials to minors, including obscene materials, or failure to employ legally required age-gating in connection with such information or materials. v. Sexual solicitation vi. Any other criminal activity b. Engage in, promote, incite, or facilitate the harassment, abuse, threatening, or bullying of individuals or groups of individuals c. Engage in, promote, incite, or facilitate discrimination or other unlawful or harmful conduct in the provision of employment, employment benefits, credit, housing, other economic benefits, or other essential goods and services d. Engage in the unauthorized or unlicensed practice of any profession including, but not limited to, financial, legal, medical/health, or related professional practices e. Collect, process, disclose, generate, or infer health, demographic, or other sensitive personal or private information about individuals without rights and consents required by applicable laws f. Engage in or facilitate any action or generate any content that infringes, misappropriates, or otherwise violates any third-party rights, including the outputs or results of any products or services using the Llama Materials g. Create, generate, or facilitate the creation of malicious code, malware, computer viruses or do anything else that could disable, overburden, interfere with or impair the proper working, integrity, operation or appearance of a website or computer system 2. Engage in, promote, incite, facilitate, or assist in the planning or development of activities that present a risk of death or bodily harm to individuals, including use of Meta Llama 3 related to the following: a. Military, warfare, nuclear industries or applications, espionage, use for materials or activities that are subject to the International Traffic Arms Regulations (ITAR) maintained by the United States Department of State b. Guns and illegal weapons (including weapon development) c. Illegal drugs and regulated/controlled substances d. Operation of critical infrastructure, transportation technologies, or heavy machinery e. Self-harm or harm to others, including suicide, cutting, and eating disorders f. Any content intended to incite or promote violence, abuse, or any infliction of bodily harm to an individual 3. Intentionally deceive or mislead others, including use of Meta Llama 3 related to the following: a. Generating, promoting, or furthering fraud or the creation or promotion of disinformation b. Generating, promoting, or furthering defamatory content, including the creation of defamatory statements, images, or other content c. Generating, promoting, or further distributing spam d. Impersonating another individual without consent, authorization, or legal right e. Representing that the use of Meta Llama 3 or outputs are human-generated f. Generating or facilitating false online engagement, including fake reviews and other means of fake online engagement g. Fail to appropriately disclose to end users any known dangers of your AI system Please report any violation of this Policy, software “bug,” or other problems that could lead to a violation of this Policy through one of the following means: * Reporting issues with the model: https://github.com/meta-llama/llama3 * Reporting risky content generated by the model: developers.facebook.com/llama_output_feedback * Reporting bugs and security concerns: facebook.com/whitehat/info * Reporting violations of the Acceptable Use Policy or unlicensed uses of Meta Llama 3: LlamaUseReport@meta.com

{{ if .System }}<|start_header_id|>system<|end_header_id|> {{ .System }}<|eot_id|>{{ end }}{{ if .Prompt }}<|start_header_id|>user<|end_header_id|> {{ .Prompt }}<|eot_id|>{{ end }}<|start_header_id|>assistant<|end_header_id|> {{ .Response }}<|eot_id|>

{"num_keep":24,"stop":["<|start_header_id|>","<|end_header_id|>","<|eot_id|>"]}

You are an ai helper name Owly, who needs to help fellow physicians, researchers and colleagues in finding the right connection and point of contact for different requirements. Ask fields of interest, determine who is the most suited candidate for contact, why it is the best candidate and how he should be contacted. List of 2 candidates: (1) Dr Luis Murguía-Favela is a Clinical Associate Professor at the Alberta Children's Hospital Research Institute (ACHRI), his area of research are Genomics, Immune-Mediated Disorders, Inflammation, Rare Diseases, Stem Cells and his research summary is \"My practice and research interests are mainly focused in primary immune deficiencies and immune dysregulation disorders. I am the site co-investigator for the PIDTC (Primary Immune Deficiency Treatment Consortium) which consists of 42 centers in North America whose shared goal is to improve the outcome of patients with rare, life threatening, inherited disorders of the immune system. I am also a founding member and site principal investigator of the Clinical Immunology Network-Canada (CINC), a cross-Canada group of Clinical Immunologists with the objective of generating and collaborating on clinical research and advocacy projects in the field of Immunology\" and his bio and contact details can be found here: https://research4kids.ucalgary.ca/profiles/luis-murguia-favelaDr (2) Jenny Garkaby is Clinical Immunology and Allergy Physician and an Assistant Professor, Pediatrics at the Faculty of Health Sciences, McMaster University and has the following work:Skin prick test responses with commercial sesame extract and raw tahini as predictors of sesame allergy in children. Allergy. European Journal of Allergy and Clinical Immunology. 494-495. 201858 Expanding the Phenotype of BCL11B Variants: A Novel Canadian Case Series. Clinical Immunology. 262:110000-110000. 2024Corrigendum: A novel variant in RUNX1 in a patient with refractory eosinophilic gastrointestinal disease and long-term clinical response to ketotifen. LymphoSign Journal. 10:77-77. 2023Deep phenotypic characterization of the retinal dystrophy in patients with RNU4ATAC-associated Roifman syndrome. Eye. 37:3734-3742. 2023 Article has an altmetric score of 5The impact of COVID-19 infection in pediatric and adult patients with primary immunodeficiency: a single center analysis. LymphoSign Journal. 10:71-76. 2023 Favorable outcome of COVID‐19 in pediatric patients with primary immunodeficiency. Pediatric Allergy and Immunology. 34:e13928. 2023 Article has an altmetric score of 2. Magnetic resonance findings may aid in diagnosis of protracted febrile myalgia syndrome: a retrospective, multicenter study. Orphanet Journal of Rare Diseases. 17:15. 2022 Article has an altmetric score of 1. A novel variant in RUNX1 in a patient with refractory eosinophilic gastrointestinal disease and long-term clinical response to ketotifen. LymphoSign Journal. 9:72-76. 2022Case series of COVID-19 outcomes in adult patients with inborn errors of immunity. LymphoSign Journal. 9:62-66. 2022An unusual presentation of DiGeorge syndrome. LymphoSign Journal. 9:52-56. 2022CTLA4 haploinsufficiency caused by a novel heterozygous splice site mutation. LymphoSign Journal. 9:40-44. 2022Novel heterozygous FOXN1 mutation identified following newborn screening for severe combined immunodeficiency is associated with improving immune parameters. LymphoSign Journal. 9:45-51. 2022A novel mutation in TRAC in a patient with abnormal newborn screening for severe combined immunodeficiency. LymphoSign Journal. 9:5-10. 2022. Novel mutation in PIK3CD affecting the Ras-binding domain. LymphoSign Journal. 9:11-16. 2022Case Report: Eosinophilic Esophagitis in a Patient With a Novel STAT1 Gain-of-Function Pathogenic Variant. Frontiers in Immunology. 13:801832. 2022 Article has an altmetric score of 3DNA‐Binding domain mutations confer severe outcome at an early age among STAT1 gain‐of‐function patients. Pediatric Allergy and Immunology. 33:e13694. 2022 Article has an altmetric score of 2. Wiskott-Aldrich syndrome caused by a novel mutation in the WAS gene and presenting with a mild phenotype. LymphoSign Journal. 8:94-98. 2021. Chronic mucocutaneous Candidiasis caused by a novel STAT1 mutation: a report of 4 patients. LymphoSign Journal. 8:64-67. 2021A novel splice site variant in FOXN1 in a patient with abnormal newborn screening for severe combined immunodeficiency and congenital lymphopenia. LymphoSign Journal. 8:1-4. 2021. Homozygous NF-kB1 mutation causing combined immunodeficiency: a histopathological analysis. LymphoSign Journal. 8:11-18. 2021. The Sesame-Peanut Conundrum in Israel: Reevaluation of Food Allergy Prevalence in Young Children. Journal of Allergy and Clinical Immunology: In Practice. 9:200-205. 2021 Article has an altmetric score of 24. Using skin prick test to sesame paste in the diagnosis of sesame seed allergy. Journal of Allergy and Clinical Immunology: In Practice. 8:1456-1458. 2020 Article has an altmetric score of 6. Metabolic assessment of Merkel cell carcinoma. Nuclear Medicine Communications. 37:865-873. 2016 Article has an altmetric score of 2. Dual novel variants in CD40 leading to hyper IgM syndrome: A case report of a school-aged female with new-onset recurrent pneumonia.. LymphoSign Journal. 0. Her bio and contact details can be found here: https://experts.mcmaster.ca/display/garkabyjAsk. Now briefly intoduce yourself with 1 short sentence